Invesco Biotechnology & Genome ETF
$94.94−1.50 (−1.56%)
- 0.59%
- $422M
- +39.2%
- 1.38%
- 0M sh
- $96.91
- low $70.01high $98.82
The ETF.net PBE Grade
B
Score 56 out of 100
- 7 of 17
Score 56 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Cost
The fund’s net expense ratio, ranked against its category.F19 out of 100Rank 14 of 17Mission
Whether the fund did what it promised, tested against its stated mandate.A91 out of 100Rank 1 of 9Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.B67 out of 100Rank 6 of 17Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.B63 out of 100Rank 6 of 17Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.C48 out of 100Rank 11 of 17Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.A78 out of 100Rank 3 of 17
Our read on PBE
BMost biotech ETFs buy the whole sector. PBE screens it, ranking names on momentum, quality and value, then holding about 30 US biotech and genome stocks. A quant stock-picker wearing index clothing.
The Fund seeks to track, before fees and expenses, the results of its designated biotechnology and genome benchmark index.
Why people hold it
- The Intellidex index rates companies on price momentum, earnings momentum, quality, management action and value, then lands on about 30 names. Selection, not sector beta.invesco.com
- Trading since 2005, it has been through several full biotech boom-and-bust cycles. Long tenure for a thematic fund.invesco.com
- No mandate drift: the stated job is tracking a US biotechnology and genome index, and the portfolio stays inside that lane.
- Normally keeps at least 90% of total assets in index securities, so what you see in the methodology is what you own.invesco.com
Worth knowing
- At 0.58% a year it charges more than the typical biotech ETF, and the big cap-weighted rivals (IBB, XBI, IBBQ) list lower fees. The screen isn't free.
- Roughly 30 holdings and a non-diversified structure: one bad trial readout lands harder here than in an index spread across hundreds of names.money.usnews.com
- Thinly traded next to the category's giants, so bid-ask spreads can run wider. Limit orders matter more with a fund like this.
PBE Holdings
- Stocks
- 33
- 49%
- ILMN
Sectors
- Health Care99.9%
- Financials0.1%
Geography
- United States97.12%
- Netherlands2.88%
PBE Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
PBE$13,920
Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | PBE |
|---|---|
| Year to date | +18.6% |
| 1 month | +3.8% |
| 3 months | +5.8% |
| 1 year | +39.2% |
| 3 years | +20.6% |
| 5 years | +6.0% |
| 10 years | +9.7% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | PBE |
|---|---|---|
| 2026 YTD | +18.6% | |
| 2025 | +24.8% | |
| 2024 | +1.1% | |
| 2023 | +3.7% | |
| 2022 | −10.8% | |
| 2021 | +1.5% | |
| 2020 | +25.7% |
PBE in the news
PBE Dividends
- 1.38%
- $1.33
- $0.02 per share
- Quarterly
Distribution history
PBE Risk
- 16.8%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.92
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −32.6%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.79
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
PBE Cost
0.59%
PBE0.59%
- The middle half of Biotech & Genomics funds
- Median 0.47%
13 of the 17 Biotech & Genomics funds charge less.
Other funds in Biotech & Genomics
- BFBTFirst Trust NYSE Arca Biotechnology Index FundExpense ratio 0.55%1 year return +44.7%
- BIDNAiShares Genomics Immunology and Healthcare ETFExpense ratio 0.47%1 year return +74.8%
- CSBIOALPS Medical Breakthroughs ETFExpense ratio 0.50%1 year return +31.0%
- CIBRNiShares Neuroscience and Healthcare ETFExpense ratio 0.47%1 year return +15.3%
- CGNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETFExpense ratio 0.35%1 year return —